Vorsetuzumab ( —— )

产品货号. M36867 CAS No. 1165740-62-4

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) 是抗人 CD70 抗体。Vorsetuzumab 能够增强肾癌细胞巨噬相关吞噬作用，对Burkitt 淋巴瘤具有抑制作用。

纯度: >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

规格	价格/人民币	库存	数量
2MG	￥2545	有现货
5MG	￥4813	有现货
10MG	￥7744	有现货
25MG	￥11104	有现货
50MG	￥15014	有现货
100MG	￥19814	有现货
500MG	获取报价	有现货
1G	获取报价	有现货

产品询价大包装询价加入购物车

生物学信息

产品名称

Vorsetuzumab
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) 是抗人 CD70 抗体。Vorsetuzumab 能够增强肾癌细胞巨噬相关吞噬作用，对Burkitt 淋巴瘤具有抑制作用。
产品描述

Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma.
体外实验

Vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro.Vorsetuzumab (10 μg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1).
体内实验

Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice.Animal Model:Burkitt’s lymphoma xenograft model in SRG mice Dosage:10 mg/kg Administration: Intraperitoneal injection; every other day; for 12 d Result:Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).
同义词

——
通路

Others
靶点

Other Targets
受体

Immunology/Inflammation related
研究领域

——
适应症

——

化学信息

CAS Number

1165740-62-4
分子量
分子式

——
纯度

>98% (HPLC)
溶解度

——
SMILES

——
化学全称

——

运输与储存

储存条件

(-20℃)
运输条件

With Ice Pack
稳定性

≥ 2 years

参考文献

1. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.?

计算器

浓度计算器

摩尔计算器

分子量计算器

产品手册